Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 4—April 2025
Research Letter

Spread of Dual-Resistant Mycoplasma genitalium Clone among Men, France, 2021–2022

Author affiliation: University of Bordeaux–National Centre for Scientific Research, Bordeaux, France (S. Pereyre, N. Henin, C. Bébéar); Bordeaux University Hospital, Bordeaux (S. Pereyre, C. Laurier-Nadalié, C. Balcon, A. Dolzy, M. Gardette, J. Guiraud, C. Bébéar)

Suggested citation for this article

Abstract

The 2058T macrolide resistance–associated mutation in 23S rRNA has emerged in Mycoplasma genitalium in France. Using mgpB typing, we documented the spread of a macrolide- and moxifloxacin-resistant ST159 clone, harboring the A2058T and ParC Ser83Ile mutations. In France, that clone is likely circulating among men who have sex with men.

Macrolide resistance in Mycoplasma genitalium is rapidly increasing worldwide (1). Reports have noted the spread of macrolide resistance in this species to be polyclonal (24), but a few resistant clones may be circulating, particularly in men (3). To search for the potential spread of M. genitalium macrolide-resistant clones in men in France, we performed a prospective nationwide survey to investigate the mgpB type of macrolide-resistant strains.

During September 15–October 15 in 2021 and 2022, we carried out a systematic collection of M. genitalium–positive specimens from men from diagnostic laboratories in France and detected resistance-associated mutations using 23S rRNA and parC gene Sanger sequencing (5). In cases of Sanger sequencing failure, our investigator group used the commercial kits ResistancePlus MG assay (SpeeDx, https://plexpcr.com/home-us) and MGMO qPCR (NYtor, https://www.nytor.nl; which detects 4 parC mutations associated with fluoroquinolone resistance) to increase the sensitivity of mutation detection, but those kits did not specify the mutation location. In a related investigation, members of our research team searched mutations in the quinolone resistance–determining region of DNA gyrase by Sanger sequencing among ParC-mutated strains (3). We performed typing on all macrolide-resistant strains using single nucleotide polymorphism analysis of the mgpB adhesin gene (3).

In this study, we collected M. genitalium–positive specimens from 229 male patients from 38 laboratories in France in 2021 and from 191 male patients from 37 laboratories in 2022. The overall prevalence of macrolide-resistant mutations was 53.2% (95% CI 47.9%–58.3%), and the percentage of fluoroquinolone resistant mutations was 25.2% (95% CI 20.8%–30.1%).

The most frequent macrolide resistance–associated mutation was A2059G (46.6%, Escherichia coli numbering), followed by the A2058T substitution (33.5%) and the A2058G mutation (19.5%). The proportion of A2058T transversion increased significantly in 2022 compared with data from 2018 (18.8% in 2018 vs. 33.5% in 2021–2022, p = 0.01) (5). Strains with the A2058T substitution harbored significantly more fluoroquinolone resistance–associated Ser83Ile substitutions in ParC (66.0%, M. genitalium numbering) than those harboring other macrolide resistance–associated mutations (14.6%; p<0.001) and the 23S rRNA wild-type strains (4.3%; p<0.001) (Table). The A20258T substitution was more frequently detected in men who have sex with men (MSM) (86.7%) and in the Paris area (49.1%) (Table).

Figure

Maximum-likelihood tree in a study of spread of dual-resistant Mycoplasma genitalium clone among men, France, 2021–2022. The tree is based on the mgpB type of 163 successfully mgpB-typed M. genitalium–positive specimens harboring macrolide resistance–associated mutations. The tree was inferred using the maximum-likelihood method based on the Tamura 3–parameter model (T92 general plus invariable site model) constructed in MEGA7 (https://www.megasoftware.net). Branch support values were generated from 100 bootstrap replicates. The M. genitalium G37 strain (American Type Culture Collection no. 33530, https://www.atcc.org) sequence was used as a reference. The phylogenetic tree was annotated from the center to the periphery with the specimen name, the mgpB type, the macrolide resistance–associated mutation (Escherichia coli numbering), the fluoroquinolone resistance–associated ParC and GyrA mutations (M. genitalium numbering), and the geographic origin of the patient. Specimen names that were mgpB ST159 are highlighted in red. The phylogenetic tree was displayed and annotated using iTOL version 6 (https://itol.embl.de). Scale bar indicates the branch length corresponding to a genetic distance of 0.01, which indicates the average number of nucleotide substitutions per site.

Figure. Maximum-likelihood tree in a study of spread of dual-resistant Mycoplasma genitalium clone among men, France, 2021–2022. The tree is based on the mgpB type of 163 successfully ...

mgpB typing of macrolide-resistant specimens revealed 47 distinct sequence types (STs), including 16 new types numbered ST339, ST347, ST350–ST356, and ST359–ST365 (Figure 1). ST159 was the most frequent ST, representing 20.2% (33 of 163 specimens with successful mgpB typing among the 185 macrolide-resistant specimens). All ST159 strains for which the nature of the mutation could be determined harbored both the A2058T transversion in 23S rRNA and the Ser83Ile substitution in ParC (Figure). Moreover, 94.1% of ST159 were from MSM or bisexual persons, and 63.6% (21/33) were from the Paris region. All 5 strains harboring a substitution at position Asp99 (M. genitalium numbering) in GyrA—which is a position where mutations increase the likelihood of moxifloxacin failure (6)—were ST159, of which 4 harbored an A2058T transversion in 23S rRNA and 1 had an undefined 23S rRNA mutation (Table, Figure).

Two studies have reported an increased prevalence of the A2058T mutation, one in the Netherlands and the other in Belgium, but those studies did not perform typing (7,8). In Spain, the emergence of the A20258T substitution has contributed to increasing macrolide resistance (9). A clonal spread was not retained by the authors despite a lower genetic diversity than expected. During 2018–2019, 8 MSM who lived in Paris were infected by a macrolide-resistant ST159 strain harboring a Ser83Ile ParC mutation, but the nature of the 23S rRNA mutation was not determined (3). Considering those data, we typed all the M. genitalium strains harboring the A2058T substitution detected in our previous 2018–2020 study (5). In total, 82.4% (28/34) A2058T strains belonged to ST159, suggesting that the A2058T-ST159 clone may have been spreading undetected for several years.

The limitations of this study were that 41.7% of the HIV and 55.2% of the sexual behavior data were missing, and only specimens harboring macrolide-resistant isolates were mgpB-typed. However, we previously showed that ST159 was much more prevalent among macrolide-resistant strains (10.6%) than among susceptible strains (0.2%) and was particularly prevalent in MSM (3). Thus, we strongly suspect the diffusion of a dual-resistant M. genitalium clone. Our research suggests that macrolide resistance detection kits would benefit from displaying the A2058T mutation in 23S rRNA, which is predictive of the fluoroquinolone resistance–associated mutation and thus of the possible failure of the first- and second-line treatments for M. genitalium infections. Considering the few therapeutic options in cases of macrolide and moxifloxacin resistance (10), the spread of such a dual-resistant clone is of concern.

In conclusion, we report an increase in the proportion of the A2058T mutation among macrolide-resistant M. genitalium strains in France during 2021–2022. We also note the spread of a dual-resistant 23S rRNA A2058T-ParC Ser83Ile M. genitalium ST159 clone, most likely circulating in MSM from the Paris, France, area.

Dr. Pereyre is a clinical microbiologist at Bordeaux University Hospital and the French National Reference Center for Sexually Transmitted Bacterial Infections. Her research interests include antibiotic resistance and typing and detection methods of human mycoplasmas.

Top

Acknowledgments

Members of the investigator group (city): Alauzet Corentine (Nancy), Amzalag Jonas (Saint-Denis), Auger Gabriel (Rennes), Bador Julien (Dijon), Barnaud Guilène (Colombes), Barrial-Lochet Kildie (Valence), Beby-Defaux Agnès (Poitiers), Bianchi Anne (Bondy), Bonzon Lucas (Montpellier), Bourgeois-Nicolaos Nadège (Clamart), Breit Laure (Colmar), Caméléna François (Paris), Chorda Camille (Aix-en-Provence), Coudène Passcal (Rodez), Daure Sophie (Montluçon), Duchamp-Dominé Marie (Toulon), Duployez Claire (Lille), Ebel Anne (Ivry-Sur-Seine), Edouard Sophie (Marseille), Ennouchi Franck (Montreuil-Juigné), Floch Pauline (Toulouse), Gibaud-Papin Sophie-Anne (Nantes), Gonzalo Sylvie (Saint-Etienne), Grob Anne (Marseille), Guillaume Clémence (Orléans), Huck Sébastien (Strasbourg), Jabnoune Inès (Saint-Denis), Koebel Christelle (Strasbourg), Lanotte Philippe (Tours), Le Bars Hervé (Brest), Malandain Damasie (Caen), Marque Juillet Stéphanie (Versailles), Mendes Lucile (Cahors), Patoz Pierre (Tourcoing), Pierrat Gautier (Paris), Potiron Grégoire (La Roche-sur-Yon), Potron Anaïs (Besançon), Rault Jean-Philippe (Metz), Rondinaud Emilie (Paris), Roumanet Frédérique (Décines), Roux Anne-Laure (Boulogne), Saïd-Delattre Ophélie (Levallois-Perret), Salord Hélène (Lyon), Trombert Sabine (Saint-Ouen-l'Aumône), Valade Hélène (Bordeaux), Zouak Fatma (Dijon).

Access to the newly described mgpB types ST339, ST347, ST350–ST356, and ST359–ST365 can be found in Genbank under accession nos. PP737211, ON933574, PP737220–PP737226, and PP737229–PP737235.

Remnants of specimens were preserved at the Centre de Resource Biologique-Bordeaux Biothèque Santé (CRB-BBS) of Bordeaux University Hospital under collection number BB-0033–00094 and authorization AC-2014–2166 from the French Ministry of Higher Education and Research with no information regarding patient identity. All patient data were anonymously reported.

This study received financial support from the French National Public Health Agency (Saint-Maurice, France) via the French National Reference Center for sexually transmitted bacterial infections.

Top

References

  1. Jensen  JS, Unemo  M. Antimicrobial treatment and resistance in sexually transmitted bacterial infections. Nat Rev Microbiol. 2024;22:43550. DOIPubMedGoogle Scholar
  2. Fernández-Huerta  M, Serra-Pladevall  J, Esperalba  J, Moreno-Mingorance  A, Fernández-Naval  C, Barberá  MJ, et al. Single-locus-sequence-based typing of the mgpB gene reveals transmission dynamics in Mycoplasma genitalium. J Clin Microbiol. 2020;58:e0188619. DOIPubMedGoogle Scholar
  3. Guiraud  J, Helary  M, Le Roy  C, Elguero  E, Pereyre  S, Bébéar  C. Molecular typing reveals distinct Mycoplasma genitalium transmission networks among a cohort of men who have sex with men and a cohort of women in France. Microorganisms. 2022;10:1587. DOIPubMedGoogle Scholar
  4. Dumke  R. Molecular tools for typing Mycoplasma pneumoniae and Mycoplasma genitalium. Front Microbiol. 2022;13:904494. DOIPubMedGoogle Scholar
  5. Pereyre  S, Laurier-Nadalié  C, Le Roy  C, Guiraud  J, Dolzy  A, Hénin  N, et al.; investigator group. Prevalence of macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in metropolitan and overseas France. Sex Transm Infect. 2023;99:25460.PubMedGoogle Scholar
  6. Murray  GL, Plummer  EL, Bodiyabadu  K, Vodstrcil  LA, Huaman  JL, Danielewski  JA, et al. gyrA mutations in Mycoplasma genitalium and their contribution to moxifloxacin failure: time for the next generation of resistance-guided therapy. Clin Infect Dis. 2023;76:218795. DOIPubMedGoogle Scholar
  7. De Baetselier  I, Smet  H, Kehoe  K, Loosen  I, Reynders  M, Mansoor  I, et al. Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022. Euro Surveill. 2024;29:2300318. DOIPubMedGoogle Scholar
  8. Braam  JF, Slotboom  B, Van Marm  S, Severs  TT, Van Maarseveen  NM, Van Zwet  T, et al. High prevalence of the A2058T macrolide resistance-associated mutation in Mycoplasma genitalium strains from the Netherlands. J Antimicrob Chemother. 2017;72:152930. DOIPubMedGoogle Scholar
  9. Piñeiro  L, Idigoras  P, Arrastia  M, Manzanal  A, Ansa  I, Cilla  G. Increases in the macrolide resistance of Mycoplasma genitalium and the emergence of the A2058T mutation in the 23S rRNA gene: clonal spread? Antibiotics (Basel). 2022;11:1492. DOIPubMedGoogle Scholar
  10. Jensen  JS, Cusini  M, Gomberg  M, Moi  H, Wilson  J, Unemo  M. 2021 European guideline on the management of Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2022;36:64150. DOIPubMedGoogle Scholar

Top

Figure
Table

Top

Suggested citation for this article: Pereyre S, Laurier-Nadalié C, Balcon C, Hénin N, Dolzy A, Gardette M, et al. Spread of dual-resistant Mycoplasma genitalium clone among men, France, 2021–2022. Emerg Infect Dis. 2025 Apr [date cited]. https://doi.org/10.3201/eid3104.241602

DOI: 10.3201/eid3104.241602

Original Publication Date: March 17, 2025

1Members of the investigator group are listed at the end of this article.

Table of Contents – Volume 31, Number 4—April 2025

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Sabine Pereyre, UMR CNRS 5234 Fundamental Microbiology and Pathogenicity, Bâtiment BBS, 2 Rue Hoffmann Martinot, Bordeaux Cedex 33076, France

Send To

10000 character(s) remaining.

Top

Page created: February 12, 2025
Page updated: March 17, 2025
Page reviewed: March 17, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external